This page is updated frequently with new Immune Disease-related patent applications.
|| List of recent Immune Disease-related patents
|Compositions and methods for treating cancer and other diseases|
Aptamers and improved aptamers are provided with enhanced efficacy for binding to target molecules in vivo or for treating cancer or other diseases. Such improvements in aptamers are provided that enhance in vivo efficacy such as binding to the target molecule or enhancing anti-cancer activity.
Memorial Sloan Kettering Cancer Center
|Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor|
The present invention is based, in part, on the identification of novel human anti-pd-1, pd-l1, and pd-l2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating pd-1, pd-l1, and/or pd-l2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-pd-1, pd-l1, and pd-l2 antibodies described herein..
|Fcrn-specific human antibody and composition for treatment of autoimmune diseases|
The present invention relates to a human antibody specific for fcrn that is a receptor with a high affinity for igg, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The fcrn-specific antibody according to the present invention can bind to fcrn non-competitively with igg or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases..
Hanall Biopharma Co., Ltd.
|Novel compounds and uses thereof|
The present invention provides novel compounds of any one of formulae (i)-(iv), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of formulae (i)-(iv) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.
|Novel anti-inflammatory agents|
Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (il-6) and/or vascular cell adhesion molecule-1 (vcam-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation..
|Substituted benzoazepines as toll-like receptor modulators|
Provided are compositions and methods useful for modulation of signaling through the toll-like receptors tlr7 and/or tlr8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease..
Array Biopharma, Inc.
The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.. .
Victoria Link Limited
|Detection and treatment of autoimmune disorders|
Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (sle) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a pd1 ligand.. .
Seattle Children's Hospital
|Method for obtaining immuno-suppressive dendritic cells|
The present invention relates to methods for producing immuno-suppressive dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from autoimmune diseases, hypersensitivity diseases, rejection on solid-organ transplantation and/or graft-versus-host disease..
|Her2/neu-specific antibodies and methods of using same|
This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
An antibody binding to ipc was obtained by using an animal cell in which a cell membrane protein associatable with ilt7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ilt family molecules and ilt7.
Sbi Biotech Co., Ltd.
Chimeric and humanized anti-histone antibodies
The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases
The present relates to interleukin 15 (il-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an il-15 mutant polypeptide having the amino acid sequence as set forth in seq id no:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.
4-alkynyl imidazole derivative and medicine comprising same as active ingredient
There are provided 4-alkynylimidazole derivatives represented by the following general formula (i) or phamaceutically acceptable salts thereof; the derivatives have a superior ep4 receptor antagonistic action and are useful as pharmaceuticals for the treatment of diseases associated with the ep4 receptor, for example, as anti-inflammatory and/or analgesic drugs for inflammatory diseases and diseases that involve various kinds of pains, and further as pharmaceuticals for the treatment of immune diseases that result from inflammations as evoked by tissue destruction due to the activation of th1 cells and/or th17 cells:. .
Kaken Pharmaceutical Co., Ltd.
Composition of mesenchymal stem cells
This invention relates in general to a mesenchymal stem cell (msc) therapy. This invention further relates to the isolation and applications of gingiva derived mesenchymal stem cells.
University Of Southern California
Substituted benzoazepines as toll-like receptor modulators
Provided are compositions and methods useful for modulation of signaling through the toll-like receptors tlr7 and/or tlr8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease..
Array Biopharma, Inc.
Autoimmune disease treatments
There are provided, inter alia, methods and compositions to treat autoimmune disease including invasiveness of fibroblast-like synoviocytes in rheumatoid arthritis.. .
La Jolla Institute For Allergy And Immunology
Anti-tnf- / anti-il-23 bispecific antibodies
Bispecific antibodies are provided that bind tumor necrosis factor alpha (tnfα) and the p19 subunit of interleukin-23 (il-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both tnfα and il-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including inflammatory bowel disease, such as crohn's disease and ulcerative colitis, axial spondyloarthropathy, rheumatoid arthritis and psoriatic arthritis..
Eli Lilly And Company
Inhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
Piperidinyl benzoimidazole derivatives as mpge-1 inhibitors
The compounds (r)-1-(5-chloro-6-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1h-benzo[d]imidazol-2-yl)-n-(tetrahydrofuran-3-yl)piperidine-4-carboxamide and (r)-1-(6-chloro-1-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1h-benzo[d]imidazol-2-yl)-n-(tetrahydrofuran-3-yl)piperidine-4-carboxamide, as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising any one of these compounds. The compounds are useful for the treatment and/or prevention of a disorder selected from an inflammatory disease; an autoimmune disease; pain; a breathing disorder; cancer; a cardiovascular disease; a neurodegenerative disease; a bone disease; a disorder due to familial adenomatous polyposis (fap) condition; overactive bladder; fever; and inflammation-related anorexia..
Inhibitors of cyclin-dependent kinase 7 (cdk7)
The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.
Immune Disease topics: Immune Disease, Autoimmune, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Immune Disorder, Transplant, Autoimmune Disorders, Type 1 Diabetes, Autoimmune Disorder, Proliferative Disorder, Signs And Symptoms, Proliferative, Antagonist, Recurrence
Follow us on Twitter
This listing is a sample listing of patent applications related to Immune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.